<?xml version="1.0" encoding="UTF-8"?>
<p>HDAC inhibitors have been extensively studied in the treatment of tumour and other epigenetic disorders
 <xref rid="CIT0020" ref-type="bibr">
  <sup>20</sup>
 </xref>. According to the chemical structure, HDACIs are divided into groups, including hydroxamic acids, aminobenzamides, cyclic peptides, carboxylic acids, and hybrid molecules
 <xref rid="CIT0004" ref-type="bibr">
  <sup>4</sup>
 </xref>. Suberoylanilide hydroxamic acid (SAHA)
 <xref rid="CIT0022" ref-type="bibr">
  <sup>22</sup>
 </xref> and FK228
 <xref rid="CIT0023" ref-type="bibr">
  <sup>23</sup>
 </xref> have been approved by US Food and Drug Administration (FDA) for the treatment of refractory cutaneous T-cell lymphoma (CTCL). PDX101
 <xref rid="CIT0024" ref-type="bibr">
  <sup>24</sup>
 </xref> and LBH589
 <xref rid="CIT0025" ref-type="bibr">
  <sup>25</sup>
 </xref> have been approved for the treatment of peripheral T-cell lymphoma (PTCL) and multiple myeloma, respectively. Chidamide
 <xref rid="CIT0026" ref-type="bibr">
  <sup>26</sup>
 </xref> is a benzamide HDACI approved by Chinese Food and Drug Administration (CFDA) for the treatment of relapsed or refractory PTCL.
</p>
